[1] AI-HAJJ M, WICHA M S, BENITO-HERNANDEZ A. Prospective identification of tumorigenic breast cancer cells. 2003
[2] SINGH S K, CLARKE I D, TERASAKI M. Identification of a cancer stem cell in human brain tumors. 2003
[3] MAZURIER F, GAN O I, MCKENZIE J L. Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture -induced stem cell impairment. 2004
[4] HOPE K, JIN L, DICK J E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. 2004(7). doi:10.1038/ni1080
[5] DICK J E. Complexity of the human acute myeloid leukemia stem cell compartment:implications for therapy, 2005
[6] PASSEGU(G) E, JAMIESON C M, AILLES L E. Normal and leukemic hematopoiesis:Normal and leukemic hematopoiesis:are leukemias a stem cell disorder or a reacquisition of stem cell characteristics-, 2003
[7] GUZMAN M L, JORDAN C T. Considerations for Targeting Malignant Stem Cells in Leukemia. 2004
[8] COZZIO A, PASSEGUE E, AYTON P M. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. 2003
[9] GUAN Y, GERHARD B, HOGGE D E. Detection,isolation,and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). 2003. doi:10.1182/blood-2002-10-3062
[10] LESSARD J, SAUVAGEAU G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. 2003(6937). doi:10.1038/nature01572
[11] XU Q, SIMPSON S E, SCIALLA T J. Survival of acute myeloid leukemia cells requires PI3 kinase activation. 2003. doi:10.1182/blood-2002-11-3429
[12] WIERENGA P K, SETROIKROMO R, KAMPS G. Differences in heat sensitivity between normal and acute myeloid leukemic stem cells:feasibility of hyperthermic purging of leukemic cells from autologous stem cell grafts. 2003
[13] GUZMAN M L, SWIDERSKI C F, HOWARD D S. Preferential induction of apoptosis for primary human leukemic stem cells. 2002
[14] FEURING-BUSKE M, FRANKEL A E, ALEXANDER R L. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. 2002
[15] TESTA U, RICCIONI R, DIVERIO D. Interleukin-3 receptor in acute leukaemia. 2004(2). doi:10.1038/sj.leu.2403224
[16] HOGGE D E, FEURING-BUSKE M, GERHARD B. The efficacy of diphtheria-growth factor fusion proteins is enhanced by coadministration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. 2004(11). doi:10.1016/j.leukres.2004.03.015
[17] PASSEGUE′ E, WAGNER E F, WEISSMAN I L. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. 2004. doi:10.1016/j.cell.2004.10.010
[18] JAMIESON C H, AILLES L E, DYLLA S J. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML N. 2004
[19] HOLTZ M S, BHATIA R. Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells. 2004(2). doi:10.1080/1042819031000151905
[20] GRAHAM S M, JORGENSEN H G, ALLAN E. Primitive,quiescent,Philadelphiapositive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. 2002. doi:10.1182/blood.V99.1.319
[21] BHATIA R, HOLTZ M, NIU N. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. 2003
[22] FUJISAKI T, OTSUKA T, GONDO H. Bestatin selectively suppresses the growth of leukemic stem/progenitor cells with BCR/ABL mRNA transcript in patients with chronic myelogeneous leukemia. 2003. doi:10.1016/S1567-5769(3)00083-3
[23] COX C V, EVELY R S, OAKHILL A. Characterisation of acute lymphoblastic leukaemia progenitor cells, 2004
[24] GEORGE A A, FRANKLIN J, KERKOF K. Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia. 2001
[25] HOTFILDER M, R-TTGERS S, ROSEMANN A. Immature CD34+CD19-progenitor/stem cells in TEL/A ML 1-positive acute lymphoblastic leukemia are genetically and functionally normal, 2002
[26] PINE S R, WIEMELS J L, JAYABOSE S. TEL-AML1 fusion precedes differentiation to pre-B cells in childhood acute lymphoblastic leukemia. 2003. doi:10.1016/S0145-2126(2)00183-2
[27] MATSUI W, HUFF C A, WANG Q J. Characterization of clonogenic multiple myeloma cells. 2004
[28] TREON S P, PILARSKI L M, BELCH A R. CD20-directed serotherapy in patients with multiple myeloma:biologic considerations and therapeutic applications, 2002 |
